Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia

Schizophrenia Bulletin

Volumn 41, Issue 4, 2015, Pages 835-846

  Do, Kim Q ^a   Cuenod, Michel ^a   Hensch, Takao K ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HARVARD UNIVERSITY   (United States)

Author keywords

GABA; myelin; NAC; oligodendrocyte; oxidative stress; parvalbumin; perineuronal net

Indexed keywords

ANTIOXIDANT; MYELIN; PARVALBUMIN;

ARTICLE; BRAIN DEVELOPMENT; CELL FUNCTION; CELL STRUCTURE; HOMEOSTASIS; HUMAN; INTERNEURON; MYELINATION; NERVE CELL EXCITABILITY; NERVE CELL INHIBITION; NERVE CELL LESION; NERVE CELL PLASTICITY; NEUROBIOLOGY; NONHUMAN; OLIGODENDROGLIA; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARVALBUMIN POSITIVE INTERNEURON; PERINEURONAL NET; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; ANIMAL; BRAIN; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; HUMANS; NEURONAL PLASTICITY; OXIDATIVE STRESS; SCHIZOPHRENIA;

EID: 84936768955     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv065     Document Type: Article

References (165)

1. Insel TR. Rethinking schizophrenia. Nature. 2010;468:187-193.
2. Gross G, Huber G, Klosterkotter J, et al. Bonner Skala für die Beurteilung von Basissymptomen. Berlin: Springer; 1987.
3. Parnas J, Bovet P, Zahavi D. Schizophrenic autism: clinical phenomenology and pathogenetic implications. World Psychiatry. 2002;1:131-136.
4. Parnas J, Henriksen MG. Disordered self in the schizophrenia spectrum: A clinical and research perspective. Harv Rev Psychiatry. 2014;22:251-265.
5. Picard F, Friston K. Predictions, perception, and a sense of self. Neurology. 2014;83:1112-1118.
6. Ford JM, Mathalon DH. Electrophysiological evidence of corollary discharge dysfunction in schizophrenia during talking and thinking. J Psychiatr Res. 2004;38:37-46.
7. Crabtree GW, Gogos JA. Synaptic plasticity, neural circuits, and the emerging role of altered short-term information processing in schizophrenia. Front Synaptic Neurosci. 2014;6:28.
8. Takesian AE, Hensch TK. Balancing plasticity/stability across brain development. Prog Brain Res. 2013;207:3-34.
9. Hensch TK. Critical period plasticity in local cortical circuits. Nat Rev Neurosci. 2005;6:877-888.
10. Fukuda T, Kosaka T, Singer W, Galuske RA. Gap junctions among dendrites of cortical GABAergic neurons establish a dense and widespread intercolumnar network. J Neurosci. 2006;26:3434-3443.
11. Bartos M, Vida I, Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci. 2007;8:45-56.
12. Fries P, Nikolić D, Singer W. The gamma cycle. Trends Neurosci. 2007;30:309-316.
13. Cardin JA, Carlén M, Meletis K, et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature. 2009;459:663-667.
14. Fuchs EC, Zivkovic AR, Cunningham MO, et al. Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron. 2007;53:591-604.
15. Gulyás AI, Szabó GG, Ulbert I, et al. Parvalbumin-containing fast-spiking basket cells generate the field potential oscillations induced by cholinergic receptor activation in the hippocampus. J Neurosci. 2010;30:15134-15145.
16. Massi L, Lagler M, Hartwich K, Borhegyi Z, Somogyi P, Klausberger T. Temporal dynamics of parvalbumin-expressing axo-axonic and basket cells in the rat medial prefrontal cortex in vivo. J Neurosci. 2012;32:16496-16502.
17. Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 2009;459:698-702.
18. Korotkova T, Fuchs EC, Ponomarenko A, von Engelhardt J, Monyer H. NMDA receptor ablation on parvalbuminpositive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron. 2010;68:557-569.
19. Wulff P, Ponomarenko AA, Bartos M, et al. Hippocampal theta rhythm and its coupling with gamma oscillations require fast inhibition onto parvalbumin-positive interneurons. Proc Natl Acad Sci U S A. 2009;106:3561-3566.
20. Uhlhaas PJ, Roux F, Rodriguez E, Rotarska-Jagiela A, Singer W. Neural synchrony and the development of cortical networks. Trends Cogn Sci. 2010;14:72-80.
21. Bavelier D, Levi DM, Li RW, Dan Y, Hensch TK. Removing brakes on adult brain plasticity: from molecular to behavioral interventions. J Neurosci. 2010;30:14964-14971.
22. Dickendesher TL, Baldwin KT, Mironova YA, et al. NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans. Nat Neurosci. 2012;15:703-712.
23. Atwal JK, Pinkston-Gosse J, Syken J, et al. PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science. 2008;322:967-970.
24. Bochner DN, Sapp RW, Adelson JD, et al. Blocking PirB up-regulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia. Sci Transl Med. 2014;6:258ra140.
25. Morishita H, Miwa JM, Heintz N, Hensch TK. Lynx1, a cholinergic brake, limits plasticity in adult visual cortex. Science. 2010;330:1238-1240.
26. Donato F, Rompani SB, Caroni P. Parvalbumin-expressing basket-cell network plasticity induced by experience regulates adult learning. Nature. 2013;504:272-276.
27. Yang EJ, Lin EW, Hensch TK. Critical period for acoustic preference in mice. Proc Natl Acad Sci U S A. 2012;109(suppl 2):17213-17220.
28. Gervain J, Vines BW, Chen LM, et al. Valproate reopens critical-period learning of absolute pitch. Front Syst Neurosci. 2013;7:102.
29. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008;31:234-242.
30. O'Donnell P. Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models. Schizophr Bull. 2011;37:484-492.
31. Wang AY, Lohmann KM, Yang CK, et al. Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin-and somatostatin-positive interneurons in the parahippocampal region. Acta Neuropathol. 2011;122:615-626.
32. Zhang ZJ, Reynolds GP. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res. 2002;55:1-10.
33. Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35:57-67.
34. Mauney SA, Athanas KM, Pantazopoulos H, et al. Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia. Biol Psychiatry. 2013;74:427-435.
35. Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S. Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch Gen Psychiatry. 2010;67:155-166.
36. McNally JM, McCarley RW, Brown RE. Impaired GABAergic neurotransmission in schizophrenia underlies impairments in cortical gamma band oscillations. Curr Psychiatry Rep. 2013;15:346.
37. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010;11:100-113.
38. Uhlhaas PJ, Singer W. Neuronal dynamics and neuropsychiatric disorders: toward a translational paradigm for dysfunctional large-scale networks. Neuron. 2012;75:963-980.
39. Atallah BV, Bruns W, Carandini M, Scanziani M. Parvalbumin-expressing interneurons linearly transform cortical responses to visual stimuli. Neuron. 2012;73:159-170.
40. Roux F, Wibral M, Mohr HM, Singer W, Uhlhaas PJ. Gamma-band activity in human prefrontal cortex codes for the number of relevant items maintained in working memory. J Neurosci. 2012;32:12411-12420.
41. Rouhinen S, Panula J, Palva JM, Palva S. Load dependence of beta and gamma oscillations predicts individual capacity of visual attention. J Neurosci. 2013;33:19023-19033.
42. Carlén M, Meletis K, Siegle JH, et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry. 2012;17:537-548.
43. Carlson GC, Talbot K, Halene TB, et al. Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proc Natl Acad Sci U S A. 2011;108:E962-E970.
44. Fazzari P, Paternain AV, Valiente M, et al. Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature. 2010;464:1376-1380.
45. Hikida T, Jaaro-Peled H, Seshadri S, et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci U S A. 2007;104:14501-14506.
46. Wen L, Lu YS, Zhu XH, et al. Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proc Natl Acad Sci U S A. 2010;107:1211-1216.
47. Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol. 2011;93:23-58.
48. Stevens HE, Su T, Yanagawa Y, Vaccarino FM. Prenatal stress delays inhibitory neuron progenitor migration in the developing neocortex. Psychoneuroendocrinology. 2013;38:509-521.
49. Jenkins TA, Harte MK, Stenson G, Reynolds GP. Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat. Behav Brain Res. 2009;205:355-359.
50. Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun. 2008;22:469-486.
51. Dell'Anna E, Geloso MC, Magarelli M, Molinari M. Development of GABA and calcium binding proteins immunoreactivity in the rat hippocampus following neonatal anoxia. Neurosci Lett. 1996;211:93-96.
52. Komitova M, Xenos D, Salmaso N, et al. Hypoxia-induced developmental delays of inhibitory interneurons are reversed by environmental enrichment in the postnatal mouse forebrain. J Neurosci. 2013;33:13375-13387.
53. Callahan LS, Thibert KA, Wobken JD, Georgieff MK. Early-life iron deficiency anemia alters the development and long-term expression of parvalbumin and perineuronal nets in the rat hippocampus. Dev Neurosci. 2013;35:427-436.
54. Brenhouse HC, Andersen SL. Nonsteroidal anti-inflammatory treatment prevents delayed effects of early life stress in rats. Biol Psychiatry. 2011;70:434-440.
55. Harte MK, Powell SB, Swerdlow NR, Geyer MA, Reynolds GP. Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. J Neural Transm. 2007;114:893-898.
56. Schiavone S, Sorce S, Dubois-Dauphin M, et al. Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry. 2009;66:384-392.
57. Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumincontaining interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci. 2009;29:2344-2354.
58. Tseng KY, Lewis BL, Hashimoto T, et al. A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons. J Neurosci. 2008;28:12691-12699.
59. Chew LJ, Fusar-Poli P, Schmitz T. Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia. Dev Neurosci. 2013;35:102-129.
60. Davis KL, Stewart DG, Friedman JI, et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003;60:443-456.
61. Takahashi N, Sakurai T, Davis KL, Buxbaum JD. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol. 2011;93:13-24.
62. Uranova NA, Vikhreva OV, Rachmanova VI, Orlovskaya DD. Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia: A postmortem morphometric study. Schizophr Res Treatment. 2011;2011:325789.
63. Byne W, Kidkardnee S, Tatusov A, Yiannoulos G, Buchsbaum MS, Haroutunian V. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr Res. 2006;85:245-253.
64. Hof PR, Haroutunian V, Copland C, Davis KL, Buxbaum JD. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem Res. 2002;27:1193-1200.
65. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: A study from the Stanley Neuropathology Consortium. Schizophr Res. 2004;67:269-275.
66. Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res. 2007;94:273-280.
67. Vostrikov V, Uranova N. Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders. Schizophr Res Treatment. 2011;2011:174689.
68. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis. 2006;21:531-540.
69. Hakak Y, Walker JR, Li C, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 2001;98:4746-4751.
70. Tkachev D, Mimmack ML, Ryan MM, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362:798-805.
71. Katsel P, Davis KL, Li C, et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology. 2008;33:2993-3009.
72. Whitford TJ, Ford JM, Mathalon DH, Kubicki M, Shenton ME. Schizophrenia, myelination, and delayed corollary discharges: A hypothesis. Schizophr Bull. 2012;38:486-494.
73. Fitzsimmons J, Kubicki M, Shenton ME. Review of functional and anatomical brain connectivity findings in schizophrenia. Curr Opin Psychiatry. 2013;26:172-187.
74. Kanaan RA, Kim JS, Kaufmann WE, Pearlson GD, Barker GJ, McGuire PK. Diffusion tensor imaging in schizophrenia. Biol Psychiatry. 2005;58:921-929.
75. Kyriakopoulos M, Bargiotas T, Barker GJ, Frangou S. Diffusion tensor imaging in schizophrenia. Eur Psychiatry. 2008;23:255-273.
76. Samartzis L, Dima D, Fusar-Poli P, Kyriakopoulos M. White matter alterations in early stages of schizophrenia: A systematic review of diffusion tensor imaging studies. J Neuroimaging. 2014;24:101-110.
77. Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol. 2008;295:C849-C868.
78. Jones DP. Redox sensing: orthogonal control in cell cycle and apoptosis signalling. J Intern Med. 2010;268:432-448.
79. Kann O, Huchzermeyer C, Kovács R, Wirtz S, Schuelke M. Gamma oscillations in the hippocampus require high complex I gene expression and strong functional performance of mitochondria. Brain. 2011;134:345-358.
80. Harris JJ, Jolivet R, Attwell D. Synaptic energy use and supply. Neuron. 2012;75:762-777.
81. Kann O, Papageorgiou IE, Draguhn A. Highly energized inhibitory interneurons are a central element for information processing in cortical networks. J Cereb Blood Flow Metab. 2014;34:1270-1282.
82. Do K, Trebesinger A, Kirsten-Kruger M, et al. Schizophrenia: glutathione deficit in cerebro spinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721-3728.
83. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14:123-130.
84. Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers. 2006;22:83-93.
85. Cabungcal JH, Steullet P, Kraftsik R, Cuenod M, Do KQ. Early-life insults impair parvalbumin interneurons via oxidative stress: reversal by N-acetylcysteine. Biol Psychiatry. 2013;73:574-582.
86. Cabungcal JH, Steullet P, Morishita H, et al. Perineuronal nets protect fast-spiking interneurons against oxidative stress. Proc Natl Acad Sci U S A. 2013;110:9130-9135.
87. Steullet P, Cabungcal JH, Kulak A, et al. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci. 2010;30:2547-2558.
88. Morishita H, Cabungcal JH, Chen Y, Do KQ, Hensch TK. Prolonged period of cortical plasticity upon redox dysregulation in fast-spiking interneurons. Biol Psychiatry. doi: 10. 016/j.biopsych.2014.12.026. [Epub ahead of print].
89. Pitts MW, Raman AV, Hashimoto AC, Todorovic C, Nichols RA, Berry MJ. Deletion of selenoprotein P results in impaired function of parvalbumin interneurons and alterations in fear learning and sensorimotor gating. Neuroscience. 2012;208:58-68.
90. Lucas EK, Markwardt SJ, Gupta S, et al. Parvalbumin deficiency and GABAergic dysfunction in mice lacking PGC-1alpha. J Neurosci. 2010;30:7227-7235.
91. Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007;318:1645-1647.
92. Cabungcal JH, Nicolas D, Kraftsik R, Cuénod M, Do KQ, Hornung JP. Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol Dis. 2006;22:624-637.
93. Kulak A, Steullet P, Cabungcal JH, et al. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxid Redox Signal. 2013;18:1428-1443.
94. Steullet P, Cabungcal JH, Kulak A, Cuenod M, Schenk F, Do KQ. Glutathione deficit in animal models of schizophrenia. In: O'Donnell P, ed. Animal Models of Schizophrenia and Related Disorders. New York, NY: Humana Press; 2011:149-188.
95. Kulak A, Cuenod M, Do KQ. Behavioral phenotyping of glutathione-deficient mice: relevance to schizophrenia and bipolar disorder. Behav Brain Res. 2012;226:563-570.
96. Lataster J, Collip D, Ceccarini J, et al. Psychosocial stress is associated with in vivo dopamine release in human ventromedial prefrontal cortex: A positron emission tomography study using [F]fallypride. Neuroimage. 2011;58:1081-1089.
97. Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int. 1998;32:117-131.
98. Rabinovic AD, Hastings TG. Role of endogenous glutathione in the oxidation of dopamine. J Neurochem. 1998;71:2071-2078.
99. Beurdeley M, Spatazza J, Lee HH, et al. Otx2 binding to perineuronal nets persistently regulates plasticity in the mature visual cortex. J Neurosci. 2012;32:9429-9437.
100. Miyata S, Komatsu Y, Yoshimura Y, Taya C, Kitagawa H. Persistent cortical plasticity by upregulation of chondroitin 6-sulfation. Nat Neurosci. 2012;15:414-422.
101. Musiek ES, Lim MM, Yang G, et al. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J Clin Invest. 2013;123:5389-5400.
102. Kobayashi Y, Ye Z, Hensch TK. Clock genes control cortical critical period timing. Neuron. 2015;86:264-275.
103. Cabungcal JH, Counotte DS, Lewis EM, et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron. 2014;83:1073-1084.
104. Penschuck S, Flagstad P, Didriksen M, Leist M, Michael-Titus AT. Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Eur J Neurosci. 2006;23:279-284.
105. Fonnum F, Lock EA. The contributions of excitotoxicity, glutathione depletion and DNA repair in chemically induced injury to neurones: exemplified with toxic effects on cerebellar granule cells. J Neurochem. 2004;88:513-531.
106. Boley AM, Perez SM, Lodge DJ. A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia. Schizophr Res. 2014;157:238-243.
107. Gill KM, Grace AA. Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model. Int J Neuropsychopharmacol. 2014;17:1609-1619.
108. Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. Acta Neuropathol. 2010;119:37-53.
109. Cammer W. Carbonic anhydrase in oligodendrocytes and myelin in the central nervous system. Ann N Y Acad Sci. 1984;429:494-497.
110. El Waly B, Macchi M, Cayre M, Durbec P. Oligodendrogenesis in the normal and pathological central nervous system. Front Neurosci. 2014;8:145.
111. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol. 2000;62:649-671.
112. Baud O, Greene AE, Li J, Wang H, Volpe JJ, Rosenberg PA. Glutathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J Neurosci. 2004;24:1531-1540.
113. Juurlink BH, Thorburne SK, Hertz L. Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to oxidative stress. Glia. 1998;22:371-378.
114. Monin A, Baumann PS, Griffa A, et al. Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients. Mol Psychiatry. 2014;doi: 10.1038/mp.2014.88. [Epub ahead of print].
115. Noble M, Smith J, Power J, Mayer-Pr?schel M. Redox state as a central modulator of precursor cell function. Ann N Y Acad Sci. 2003;991:251-271.
116. Corcoba A SP, Duarte JM, van de Looij Y, Gruetter R, Do KQ. Impaired white matter integrity in fornix and anterior commissure in a schizophrenia mouse model of redox dysregulation. Biol Psychiatry. 2014;75:175S.
117. Li Z, Dong T, Proschel C, Noble M. Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function. PLoS Biol. 2007;5:e35.
118. Ohnuma T, Kato H, Arai H, McKenna PJ, Emson PC. Expression of Fyn, a non-receptor tyrosine kinase in prefrontal cortex from patients with schizophrenia and its correlation with clinical onset. Brain Res Mol Brain Res. 2003;112:90-94.
119. Daskalakis ZJ, Christensen BK, Fitzgerald PB, Chen R. Dysfunctional neural plasticity in patients with schizophrenia. Arch Gen Psychiatry. 2008;65:378-385.
120. McClintock SM, Freitas C, Oberman L, Lisanby SH, Pascual-Leone A. Transcranial magnetic stimulation: A neuroscientific probe of cortical function in schizophrenia. Biol Psychiatry. 2011;70:19-27.
121. Cavuş I, Reinhart RM, Roach BJ, et al. Impaired visual cortical plasticity in schizophrenia. Biol Psychiatry. 2012;71:512-520.
122. Mears RP, Spencer KM. Electrophysiological assessment of auditory stimulus-specific plasticity in schizophrenia. Biol Psychiatry. 2012;71:503-511.
123. Hasan A, Nitsche MA, Rein B, et al. Dysfunctional longterm potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav Brain Res. 2011;224:15-22.
124. Beste C, Wascher E, Dinse HR, Saft C. Faster perceptual learning through excitotoxic neurodegeneration. Curr Biol. 2012;22:1914-1917.
125. Steullet P, Cabungcal JH, Monin A, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology? Schizophr Res. 2014;doi: 10.1016/j.schres.2014.06.021. [Epub ahead of print] Review.
126. Piontkewitz Y, Arad M, Weiner I. Tracing the development of psychosis and its prevention: what can be learned from animal models. Neuropharmacology. 2012;62:1273-1289.
127. Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011;15:2011-2035.
128. Yao JK, Stanley JA, Reddy RD, Keshavan MS, Pettegrew JW. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol Psychiatry. 2002;52:823-830.
129. Keshavan MS, Stanley JA, Montrose DM, Minshew NJ, Pettegrew JW. Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an in vivo 31P MRS study. Mol Psychiatry. 2003;8:316-323.
130. Keshavan MS PJ, Ward R. Are membrane phospholipid changes in schizophrenia familial? Biol Psychiatry. 1993;33:45A.
131. Bentsen H, Solberg DK, Refsum H, et al. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry. 2011;70:97-105.
132. Arvindakshan M, Sitasawad S, Debsikdar V, et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry. 2003;53:56-64.
133. Ali HA, Afifi M, Abdelazim AM, Mosleh YY. Quercetin and omega 3 ameliorate oxidative stress induced by aluminium chloride in the brain. J Mol Neurosci. 2014;53:654-660.
134. Zugno AI, Chipindo HL, Volpato AM, et al. Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. Neuroscience. 2014;259:223-231.
135. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67:1954-1967.
136. Amminger GP, Schäfer MR, Papageorgiou K, et al. Longchain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146-154.
137. Fahey JW, Haristoy X, Dolan PM, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A. 2002;99:7610-7615.
138. Talalay P, Fahey JW, Healy ZR, et al. Sulforaphane mobilizes cellular defenses that protect skin against damage by UV radiation. Proc Natl Acad Sci U S A. 2007;104:17500-17505.
139. Gibbs A, Schwartzman J, Deng V, Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A. 2009;106:16663-16668.
140. Li Y, Zhang T, Korkaya H, et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res. 2010;16:2580-2590.
141. Guerrero-Beltrán CE, Calderón-Oliver M, Pedraza-Chaverri J, Chirino YI. Protective effect of sulforaphane against oxidative stress: recent advances. Exp Toxicol Pathol. 2012;64:503-508.
142. Mas S, Gassó P, Trias G, Bernardo M, Lafuente A. Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stress. Fundam Clin Pharmacol. 2012;26:712-721.
143. Shirai Y, Fujita Y, Hashimoto K. Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration. Clin Psychopharmacol Neurosci. 2012;10:94-98.
144. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 2013;34:167-177.
145. Mandal PK, Seiler A, Perisic T, et al. System x©-and thioredoxin reductase 1 cooperatively rescue glutathione deficiency. J Biol Chem. 2010;285:22244-22253.
146. das Neves Duarte JM, Kulak A, Gholam-Razaee MM, Cuenod M, Gruetter R, Do KQ. N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biol Psychiatry. 2012;71:1006-1014.
147. Paintlia MK, Paintlia AS, Contreras MA, Singh I, Singh AK. Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: attenuation by N-acetyl cysteine. Exp Neurol. 2008;210:560-576.
148. Cleland JH, Lutgen V, Raddatz N, Qualmann K, Choi S, Baker DA. The potential role for system xc-in schizophrenic pathology. Paper presented at: US Society for Neuroscience, 2013.
149. Lutgen V, Qualmann K, Resch J, Kong L, Choi S, Baker DA. Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc activity in the medial prefrontal cortex. Psychopharmacology (Berl). 2013;226:531-540.
150. Otte DM, Sommersberg B, Kudin A, et al. N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology. 2011;36:2233-2243.
151. M?ller M, Du Preez JL, Viljoen FP, Berk M, Harvey BH. N-acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats. Metab Brain Dis. 2013;28:687-696.
152. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-A double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361-368.
153. Bulut M, Savas HA, Altindag A, Virit O, Dalkilic A. Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J Biol Psychiatry. 2009;10:626-628.
154. Farokhnia M, Azarkolah A, Adinehfar F, et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2013;36:185-192.
155. Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008;33:2187-2199.
156. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry. 2000;57:1139-1147.
157. Carmeli C, Knyazeva MG, Cuénod M, Do KQ. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: A double-blind, randomized, placebo-controlled trial. PLoS One. 2012;7:e29341.
158. Farr SA, Poon HF, Dogrukol-Ak D, et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem. 2003;84:1173-1183.
159. Du Y, Grace AA. Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia. Neuropsychopharmacology. 2013;38:1881-1888.
160. Hensch TK, Fagiolini M, Mataga N, Stryker MP, Baekkeskov S, Kash SF. Local GABA circuit control of experiencedependent plasticity in developing visual cortex. Science. 1998;282:1504-1508.
161. Silingardi D, Scali M, Belluomini G, Pizzorusso T. Epigenetic treatments of adult rats promote recovery from visual acuity deficits induced by long-term monocular deprivation. Eur J Neurosci. 2010;31:2185-2192.
162. Stephany CE, Chan LL, Parivash SN, et al. Plasticity of binocularity and visual acuity are differentially limited by nogo receptor. J Neurosci. 2014;34:11631-11640.
163. Spatazza J, Lee HH, Di Nardo AA, et al. Choroid-plexusderived Otx2 homeoprotein constrains adult cortical plasticity. Cell Rep. 2013;3:1815-1823.
164. Norton, DJ, McBain RK, Ongur, D, et al. Perceptual training strongly improves visual motion perception in schizophrenia. Brain Cogn. 2011; 77:248-256.
165. Sawa A, Seidman LJ. Is prophylactic psychiatry around the corner? combating adolescent oxidative stress for adult psychosis and schizophrenia. Neuron. 2014;83:991-993.